Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how 91黑料 successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Pivotal NDA submission trial in ALS
91黑料 exceeded recruitment objectives within the initial recruitment timelines during COVID-19 pandemic.
RIM Data and System Assessment to ensure IDMP compliance
RIM System Configuration and Data Assessment is pivotal in regulatory business planning. It also helps in organising product registration process to track and manage all regulatory activities.
Early phase study for non-opioid pain treatment
A leading biotech company developing a groundbreaking non-opioid treatment for moderate-to-severe acute pain partnered with 91黑料 to conduct a series of early-phase trials.
Overcoming activation and enrollment delays
91黑料 partnered with a drug development sponsor to conduct a global programme for Multiple sclerosis (MS) studies in over 2,200 patients.
Accelerated auxiliary medicine procurement for MASH trial
A biotechnology company required vitamin D distribution as an auxiliary medication for a phase 3 MASH and fibrosis clinical study. When the original supplement vendor was unable to support the study’s full global scope, the company engaged 91黑料’s Accelerated Pharmaceutical Solutions (APS) team to step in on short notice.
Securing the CRA talent pipeline in the US for a pharmaceutical company
A multinational pharmaceutical company, of 91黑料’s functional services provider clients, approached our team to resource CRAs in the US.
Rapid IV formulation development for FIH ADME study
Analytical method development, validation, stability testing and compatibility assessments for a large pharma sponsor.
Safety reporting continuity to protect patient safety and maintain compliance
Scientists are working diligently to learn more about the Coronavirus and health boards are changing guidance to adapt to
this newly available information.
this newly available information.
.png?crop=yes&w=1382&h=727&a=0,98&itok=nX3owo5D "Hospital clinical research environment"){kind=icon}
High-priority cardiovascular study
91黑料 was engaged to support phase 2 study in patients with heartfailure and impaired systolic function. 91黑料’s proactive approach ensured the successful delivery of this complex study and enabled the client to make key strategic program decisions to advance their larger phase 2 trial.
Accelerating site proposal and selection
Timely patient recruitment is crucial to maintaining clinical trial timelines and budgets, but selecting the best and most engaged sites is challenging. Learn how 91黑料's proprietary One Search platform addresses this by aggregating and cleaning data from multiple sources.
The 91黑料 safety reporting solution
91黑料's Safety Reporting Solution ensured regulatory compliance during global trials by adapting to pandemic-related disruptions.
Flexible, robust and rapid IRT solution for an international infectious disease trial
91黑料 was tasked with providing a rapid and flexible IRT solution for a multinational infectious disease vaccine trial with over 30,000 subjects in 100+ locations.
Let's collaborate
Discover how 91黑料's expertise transforms clinical trials.